J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It
Prevention Of Severe Disease Consistent Across Geographies
The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.
You may also be interested in...
Coronavirus Update: At One-Year Mark, WHO Stresses Importance Of Fair Vaccine Distribution
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.
Could COVID-19 Variants Upend Global Vaccine Supply Deals?
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?
One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective
A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.